Prescription medicine
Besifloxacin Brand names: Besivance
Besifloxacin (Besivance) is a prescription medicine with an FDA approval on record since 2009. No generic is listed; pharmacies paid $44.09 per mL (Besivance 0.6% suspension) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the besifloxacin FDA label on DailyMed (effective January 12, 2026, Bausch & Lomb Americas Inc.); the NDA 22308 record on Drugs@FDA; every besifloxacin label on DailyMed.
Highlights of the record
FDA label of January 12, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageBesifloxacin ophthalmic suspension 0.6% is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans * CDC coryneform group G Corynebacterium pseudodiphtheriticum* Corynebacterium striatum* Haemophilus influenzae Moraxella catarrhalis* Moraxella lacunata* Pseudomonas aeruginosa* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus
Forms and strengths
- 6 mg/ml
Suspension.
On the market
- Earliest approval on file
- May 28, 2009 Besivance, Bausch And Lomb; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 3 of which 0 under generic applications, 3 under brand applications, repackagers included
- Last listed patent
- January 9, 2031 Besivance suspension/drops; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $44.09 per mL Besivance 0.6% suspension
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 967 through July 30, 2026
What is besifloxacin used for?
From the label: indications and usageBesifloxacin ophthalmic suspension 0.6% is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans * CDC coryneform group G Corynebacterium pseudodiphtheriticum* Corynebacterium striatum* Haemophilus influenzae Moraxella catarrhalis* Moraxella lacunata* Pseudomonas aeruginosa* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus hominis* Staphylococcus lugdunensis* Staphylococcus warneri* Streptococcus mitis group Streptococcus oralis Streptococcus pneumoniae Streptococcus salivarius * *Efficacy for this organism was studied in fewer than 10 infections. […]
FDA pharmacologic class: Quinolone Antimicrobial.
Source: FDA drug label (Besivance), Bausch & Lomb Americas Inc., effective January 12, 2026 (SPL set ff971287-5610-4f15-8392-fc974e6ff646), via openFDA; the full label on DailyMed
Is there a generic for besifloxacin (Besivance)?
No generic besifloxacin is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 4 patents for Besivance suspension/drops: the compound patent runs to January 9, 2031. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2009 earliest approval on file
- 2031 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for besifloxacin (Besivance)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $44.09 per mL (Besivance 0.6% suspension), about the same as a year earlier. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Besivance 0.6% suspension (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Besivance 0.6% suspension | Brand | $44.09 per mL | n/a | -0.3% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the besifloxacin label say about other medicines?
The besifloxacin label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Fluorescein | warnings and precautions | Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and, where appropriate, fluorescein staining. |
Source: FDA drug label (Besivance), Bausch & Lomb Americas Inc., effective January 12, 2026 (SPL set ff971287-5610-4f15-8392-fc974e6ff646), via openFDA; the full label on DailyMed
What do FAERS reports show for besifloxacin?
The FDA Adverse Event Reporting System holds 967 reports that list besifloxacin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 67 are coded as a death and 157 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other quinolone antimicrobials
- the pharmacologic class, with prices and generics
- Besifloxacin side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other